1. Clozapine as a mood stabiliser for schizoaffective disorder: Effectiveness during a three-month follow-up.
- Author
-
Peraire M, Arnau-Peiró F, Benito A, Fuertes-Saiz A, Almodóvar-Fernández I, and Haro G
- Subjects
- Humans, Male, Female, Adult, Follow-Up Studies, Middle Aged, Psychiatric Status Rating Scales, Treatment Outcome, Longitudinal Studies, Prospective Studies, Young Adult, Clozapine therapeutic use, Psychotic Disorders drug therapy, Psychotic Disorders psychology, Antipsychotic Agents therapeutic use
- Abstract
Clozapine has shown signs of effectiveness in treating symptoms of schizoaffective disorder, although little research has been carried out to specifically assess this question. The objective of this current work was to analyse the mood-stabilising effectiveness and tolerability of clozapine in patients with schizoaffective disorder. This was a prospective, longitudinal, and quasi-experimental trial with three months of follow-up in patients with refractory schizoaffective disorder (PANSS score exceeding 80). Clinical response was evaluated through monthly visits using the YMRS, MADRS, CDSS, CGI-S and UKU. Twenty-seven participants (63% men, 37% women) with a mean age of 32.56 years were included. Clozapine significantly reduced the symptoms of mania, as measured by the YMRS (pre-treatment: 16.19, post-treatment: 0.67; p < 0.01) as well as the symptoms of depression, quantified with the CDSS (pre-treatment: 6.11, post-treatment: 0.67; p < 0.01), MADRS (pre-treatment: 9.56, post-treatment: 1.07; p < 0.01), and CGI-S (pre-treatment: 4.74, post-treatment: 1.15; p < 0.01). The prescription of clozapine significantly reduced the average daily dose of neuroleptics, measured in mg of chlorpromazine (pre-treatment: 1253.55, post-treatment: 742.59; p < 0.01) and hypnosedatives, measured in mg of diazepam (pre-treatment: 33.88, post-treatment: 5.74; p < 0.05) required in these patients. Patient-perceived tolerability, measured with the UKU, also improved during follow-up (pre-treatment: 12.89, post-treatment: 8.14; p < 0.01). The efficacy of clozapine was significant for the affective symptoms of schizoaffective disorder, thereby improving patient tolerability and permitting reductions in the other medications the patients used., Competing Interests: Declaration of competing interest The authors declare that doctoral student Marc Peraire is the main author of the research presented, as well as declare that they agree with the presentation of this article by said doctoral student in his doctorate by compendium of articles. Non-doctoral authors waive the use of this article in their future PhDs. The authors declare that they have no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF